AstraZeneca headlined its third-quarter earnings update with news of a $185 million upfront licensing deal with Chinese biotech Eccogene for an orally active GLP-1 agonist
The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’
A few weeks ago on the pharmaphorum podcast, we discussed the new GLP-1 weight loss drugs and their shake-up effect on the medical weight loss industry.
Novo Nordisk has halted a phase 3 trial of its Ozempic formulation of GLP-1 agonist semaglutide in patients with type 2 diabetes and chronic kidney disease (CKD) early aft
The European Medicines Agency (EMA) has started a review of two Novo Nordisk drugs used to treat obesity and those overweight, following reports of suicidal thoughts or se
The venture capital arms of MSD and Amgen have provided $10 million in funding to Culmination Bio, a Utah start-up that aims to build the largest disease-agnostic patient
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio